Glenmark Pharmaceuticals Inc., USA, a subsidiary of Glenmark Pharmaceuticals Limited, has announced the launch of Milnacipran Hydrochloride Tablets in the US market. These tablets, available in dosages of 12.5 mg, 25 mg, 50 mg, and 100 mg, are the authorised generic version of Savella® Tablets.
According to IQVIA sales data for the 12-month period ending January 2026, the market for Savella® Tablets, encompassing all available therapeutic equivalents, achieved annual sales of approximately $102.9 million. The introduction of Glenmark’s authorised generic aims to provide a more affordable alternative to patients.
Marc Kikuchi, President & Business Head, North America, expressed excitement over the launch, stating, “We are excited to announce the launch of Milnacipran Hydrochloride Tablets, the authorised generic to Savella® Tablets. This launch further strengthens our commitment to bring to market quality and affordable alternatives for patients.”
Glenmark’s Milnacipran Hydrochloride Tablets are approved for the indications listed in Glenmark’s approved label. The company emphasises that its product is not marketed for all indications of the reference listed drug (RLD).
Glenmark Pharmaceuticals Ltd. is a global, research-led pharmaceutical company focused on innovation and accessibility, with a presence in over 80 countries. The company operates 11 manufacturing facilities and six R&D centres across four continents, delivering a diversified portfolio of branded, innovative, generics, and consumer health products.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).